Generation of the therapeutic monoclonal antibody NEO-201, derived from a cancer vaccine, which targets human malignancies and immune suppressor cells
Introduction Cancer vaccines stimulate the activation of specific humoral and cellular adaptive responses against cancer cells.Antibodies generated post vaccination can be isolated and further selected to develop highly specific and potent monoclonal antibodies (mAbs) against tumor-associated antige...
Saved in:
| Main Authors: | , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Taylor & Francis Group
2024-12-01
|
| Series: | Expert Review of Vaccines |
| Subjects: | |
| Online Access: | https://www.tandfonline.com/doi/10.1080/14760584.2024.2397011 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1839636705770995712 |
|---|---|
| author | Massimo Fantini Kwong Y. Tsang Philip M. Arlen |
| author_facet | Massimo Fantini Kwong Y. Tsang Philip M. Arlen |
| author_sort | Massimo Fantini |
| collection | DOAJ |
| description | Introduction Cancer vaccines stimulate the activation of specific humoral and cellular adaptive responses against cancer cells.Antibodies generated post vaccination can be isolated and further selected to develop highly specific and potent monoclonal antibodies (mAbs) against tumor-associated antigens.Areas covered This review describes different types of cancer vaccines, the process of the generation of the mAb NEO-201 from the Hollinshead cancer vaccine platform, the characterization of the antigen recognized by NEO-201, the ability of NEO-201 to bind and mediate the killing of cancer cells and immunosuppressive cells (gMDSCs and Tregs) through ADCC and CDC, NEO-201 preclinical and clinical toxicity and efficacy.Expert opinion To overcome the problem of poor clinical efficacy of cancer vaccines, due to the activity of immunosuppressive cells, cancer vaccines could be combined with other immunotherapeutics able to deplete immunosuppressive cells. Results from clinical trials, employing NEO-201 alone or in combination with pembrolizumab, showed that durable stabilization of disease after treatment was due to the ability of NEO-201 to target and reduce the percentage of circulating Tregs and gMDSCs.These findings provide compelling support to combine NEO-201 with cancer vaccines to reintegrate their ability to elicit a robust and durable immune adaptive response against cancer. |
| format | Article |
| id | doaj-art-1f18e28cebf54c5d90d36e6bdae7d26f |
| institution | Matheson Library |
| issn | 1476-0584 1744-8395 |
| language | English |
| publishDate | 2024-12-01 |
| publisher | Taylor & Francis Group |
| record_format | Article |
| series | Expert Review of Vaccines |
| spelling | doaj-art-1f18e28cebf54c5d90d36e6bdae7d26f2025-07-07T08:42:03ZengTaylor & Francis GroupExpert Review of Vaccines1476-05841744-83952024-12-0123181282910.1080/14760584.2024.2397011Generation of the therapeutic monoclonal antibody NEO-201, derived from a cancer vaccine, which targets human malignancies and immune suppressor cellsMassimo Fantini0Kwong Y. Tsang1Philip M. Arlen2Precision Biologics, Inc, Bethesda, MD, USAPrecision Biologics, Inc, Bethesda, MD, USAPrecision Biologics, Inc, Bethesda, MD, USAIntroduction Cancer vaccines stimulate the activation of specific humoral and cellular adaptive responses against cancer cells.Antibodies generated post vaccination can be isolated and further selected to develop highly specific and potent monoclonal antibodies (mAbs) against tumor-associated antigens.Areas covered This review describes different types of cancer vaccines, the process of the generation of the mAb NEO-201 from the Hollinshead cancer vaccine platform, the characterization of the antigen recognized by NEO-201, the ability of NEO-201 to bind and mediate the killing of cancer cells and immunosuppressive cells (gMDSCs and Tregs) through ADCC and CDC, NEO-201 preclinical and clinical toxicity and efficacy.Expert opinion To overcome the problem of poor clinical efficacy of cancer vaccines, due to the activity of immunosuppressive cells, cancer vaccines could be combined with other immunotherapeutics able to deplete immunosuppressive cells. Results from clinical trials, employing NEO-201 alone or in combination with pembrolizumab, showed that durable stabilization of disease after treatment was due to the ability of NEO-201 to target and reduce the percentage of circulating Tregs and gMDSCs.These findings provide compelling support to combine NEO-201 with cancer vaccines to reintegrate their ability to elicit a robust and durable immune adaptive response against cancer.https://www.tandfonline.com/doi/10.1080/14760584.2024.2397011Cancer immunotherapycancer vaccinesmonoclonal antibodiesNEO-201TregsgMDSCs |
| spellingShingle | Massimo Fantini Kwong Y. Tsang Philip M. Arlen Generation of the therapeutic monoclonal antibody NEO-201, derived from a cancer vaccine, which targets human malignancies and immune suppressor cells Expert Review of Vaccines Cancer immunotherapy cancer vaccines monoclonal antibodies NEO-201 Tregs gMDSCs |
| title | Generation of the therapeutic monoclonal antibody NEO-201, derived from a cancer vaccine, which targets human malignancies and immune suppressor cells |
| title_full | Generation of the therapeutic monoclonal antibody NEO-201, derived from a cancer vaccine, which targets human malignancies and immune suppressor cells |
| title_fullStr | Generation of the therapeutic monoclonal antibody NEO-201, derived from a cancer vaccine, which targets human malignancies and immune suppressor cells |
| title_full_unstemmed | Generation of the therapeutic monoclonal antibody NEO-201, derived from a cancer vaccine, which targets human malignancies and immune suppressor cells |
| title_short | Generation of the therapeutic monoclonal antibody NEO-201, derived from a cancer vaccine, which targets human malignancies and immune suppressor cells |
| title_sort | generation of the therapeutic monoclonal antibody neo 201 derived from a cancer vaccine which targets human malignancies and immune suppressor cells |
| topic | Cancer immunotherapy cancer vaccines monoclonal antibodies NEO-201 Tregs gMDSCs |
| url | https://www.tandfonline.com/doi/10.1080/14760584.2024.2397011 |
| work_keys_str_mv | AT massimofantini generationofthetherapeuticmonoclonalantibodyneo201derivedfromacancervaccinewhichtargetshumanmalignanciesandimmunesuppressorcells AT kwongytsang generationofthetherapeuticmonoclonalantibodyneo201derivedfromacancervaccinewhichtargetshumanmalignanciesandimmunesuppressorcells AT philipmarlen generationofthetherapeuticmonoclonalantibodyneo201derivedfromacancervaccinewhichtargetshumanmalignanciesandimmunesuppressorcells |